Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter licensing of Innocoll gentamicin

This article was originally published in The Gray Sheet

Executive Summary

Baxter will have exclusive rights in the U.S. to market and distribute Innocoll's gentamicinsurgical implant - a biodegradable, leave-behind antibiotic surgical sponge used as an add-on therapy for prevention and treatment of surgical site infections - when the device completes Phase III clinical trials and hopefully is approved by FDA sometime in 2009, a spokeswoman said Aug. 25. The device will be regulated as a drug and be reviewed by FDA's Center for Drug Evaluation & Research, according to the firm. Under the terms of the Innocoll deal, Baxter will pay a license fee and make contingent clinical, regulatory and commercial milestone payments, while Innocoll will supply the product and shepherd the FDA process. The product is available overseas
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT026525

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel